Ceritinib Plus Nivolumab in NSCLC Characterized by an ALK Mutation
Among patients who were naive to ALK inhibition, the overall response rate was 83% for the 450-mg dose and 60% for the 300-mg dose.
All articles by Leah Lawrence
Efforts Made in the 1960s to Curb Smoking Will Have Effects Well Into Future
Scientific models project a continued decrease in lung cancer mortality.
Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Exercise May Improve Quality of Life in Lung Cancer
Study examines increased physical activity may lower the risk for several cancers and may be beneficial for improving quality of life.
Lung Cancer Risk Reduced With Smoke-Free Ordinances
Few cases of lung cancer suspected in counties with smoke-free ordinances.
Diagnostic Test Can Identify Biomarkers to Detect Lung Cancer
A new diagnostic test and algorithm may be able to diagnose lung cancer from tumor-educated platelets.
PD-L1 Inhibitor Approved by FDA for Non-Small Cell Lung Cancer
Atezolizumab was approved for patients with non-small cell lung cancer.
Next post in Lung Cancer
